Noridian has posted a Multi Jurisdictional CAC Meeting on September 4, 2025.
The topic will be, Multi-Jurisdictional CAC Meeting Announcement - MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia.
Find it here:
https://med.noridianmedicare.com/web/jeb/policies/lcd/cac
- An "Agenda" has been posted, but it's very brief.
- Wait for the "key questions" document, which is not posted yet.
- UPDATE: 17 QUESTIONS POSTED
- https://www.dmepdac.com/palmetto/providers.nsf/Files/MolDX_Key_Questions_and_Bibliography09042025.pdf/$FILE/MolDX_Key_Questions_and_Bibliography09042025.pdf
Just for fun, this is how Chat GPT read the 17 questions in search of bias pro and con (if any).
###
###
MolDx LCD (e.g L39256) does not cover molecular Barrett's testing. It lays out a framework for coverage, but concludes no tests yet meet the framework.
- Although there are several promising molecular biomarker tests designed to further identify at-risk patients, this contractor finds that there are currently no existing tests that have demonstrated AV, CV, and clinical utility (CU) to fulfill the necessary criteria.
- This contractor will continue to monitor the evidence and may revise this determination based on the pertinent literature and society recommendations.
That version dates from 2023. Results of the public meeting might bolster the current non-coverage decision, or, might lead MolDx to flip to a favorable coverage decision. To be continued.
###
See my blog about the original 2023 decision here.
